Practical implication
Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.
The FDA has revised the labeling for ferric carboxymaltose injection (Injectafer) to include a boxed warning for symptomatic hypophosphatemia. Effective September 1, 2026, this warning emphasizes the importance of monitoring serum phosphate levels in patients at risk, particularly those receiving repeat courses of therapy.
What changed: A boxed warning regarding the risk of symptomatic hypophosphatemia has been added to the labeling of ferric carboxymaltose injection (Injectafer).
Why it matters: This change highlights serious health risks associated with Injectafer, including low phosphate levels that could lead to severe complications like muscle weakness, fatigue, and bone softening, necessitating careful monitoring and management in treated patients.
Practical implication: Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-09-01T00:00:00.000Z
- Discovered by monitor: 2026-09-01T21:41:27.363Z
Published from the regulator source ingestion pipeline after PV impact triage.
